A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study to Evaluate the Efficacy and Safety of LCZ696 Compared to Placebo After 8 Weeks Treatment in Patients With Essential Hypertension
Phase of Trial: Phase II
Latest Information Update: 01 Sep 2017
At a glance
- Drugs Sacubitril/valsartan (Primary)
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Novartis
- 31 May 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 15 Nov 2010 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 10 Sep 2010 New trial record